International Journal of Hematology and Oncology 2022, Vol 32, Num 4 Page(s): 215-219
Effect of Zoledronic Acid on Rats’ Tissue SDF-1 Expression

Zafer ARIK1, Saadettin KILICKAP2, Ugur AKPULAT3, M. Ali NAHIT SENDUR4, Y. Cetin KOCAEFE3, Mustafa ERMAN2

1Zekai Tahir Burak Women’s Health Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
2Hacettepe University, Institute of Cancer, Department of Medical Oncology, Ankara, TURKEY
3Hacettepe University Faculty of Medicine, Department of Medical Biology, Ankara, TURKEY
4Yildirim Beyazit University Department of Medical Oncology, Ankara, TURKEY

Keywords: Zoledronic acid, SDF-1, CXCR4, Lung, Liver
Zoledronic acid has been shown to inhibit cancer cell proliferation, metastasis and induce cancer cell apoptosis. Stromal Derived Factor-1 (SDF-1) is a chemokine that has been reported to be expressed markedly high in the most common metastatic sites. The aim of this study was to investigate the effect of zoledronic acid on SDF-1 mRNA expression of rats’ tissues. Rats were randomised into two groups, each containing five rats. Zoledronic acid was administered 0.1 mg/kg subcutaneously to one group. Other group was used as the control group. Seven days later, all rats were sacrificed. Levels of SDF-1 mRNA expression in tissues were measured quantitatively with RT-PCR. The median of SDF-1 mRNA relative expression in the lung was 0.80 (0.49-1.00) in the control group and 0.90 (0.61-1.42) in the zoledronic acid group (p= 0.53). The median of SDF-1 mRNA relative expression in the liver was 0.90 (0.39-1.00) in the control group and 0.93 (0.77-1.29) in the zoledronic acid group (p= 0.35). In this study, we investigated the effect of zoledronic acid on the tissue SDF-1 mRNA expression for the first time in the literature. We observed that a single dose of zoledronic acid did not change SDF-1 expression in lung and liver of rats.